Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill tested to slow Alzheimer's in High-Risk group

NCT ID NCT04693520

Summary

This study tested an oral medication called ALZ-801 in 84 people with early Alzheimer's disease who carry a specific genetic risk factor (the APOE4 gene). The main goal was to see if the drug could affect biological markers of Alzheimer's in the blood and brain over two years, and to check its safety. Participants took the pill twice daily and were monitored for changes in brain scans and blood tests related to the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER´S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Brain Research Center

    's-Hertogenbosch, Netherlands

  • Brain Research Center

    Amsterdam, Netherlands

  • Brain Research Center

    Zwolle, Netherlands

  • Motol University Hospital

    Prague, Czechia

  • St. Anne's University Hospital

    Brno, Czechia

  • Vestra Clinics

    Rychnov nad Kněžnou, Czechia

Conditions

Explore the condition pages connected to this study.